Clinical Trial

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

Study acronym: dnaJP1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical study is a multi-center, randomized, double-blind, placebo-controlled, outpatient study comparing the efficacy of combination of dnaJP1 peptide and hydroxychloroquine versus combination of placebo and hydroxychloroquine in patients with moderately to severely active RA who are naive to cs-, b-, tsp.-DMARDs. A sample size of 124 patients will be enrolled in the study. Each patient will receive either combination of dnaJP1 peptide and hydroxychloroquine or combination of placebo and hydroxychloroquine in 1:1 allocation ratio.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-05; most recent amendment 2025-08-06.
Trial Details
NCT Number NCT07013110
Lead Sponsor Prof Salvatore Albani
Collaborators: Singapore General Hospital
Conditions Rheumatoid Arthritis (RA), Rheumatology
Enrollment 124 participants
Start Date 2025-06-18
Primary Completion 2028-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2025-08-11